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Abstract
Background: The PRIMUS is a Multiple Sclerosis (MS)-specific suite of outcome measures including assessments of
QoL (PRIMUS QoL, scored 0-22) and activity limitations (PRIMUS Activities, scored 0-30). The U-FIS is a measure of
fatigue impact (scored 0-66). These measures have been fully validated previously using an MS sample with mixed
diagnoses. The aim of the present study was to validate the measures further in a specifically Relapse Remitting MS
(RRMS) sample and to provide preliminary evidence of the responder definitions (RD; also known as minimal
important difference) for these instruments.
Methods: Data were derived from a multi-country efficacy trial of MS patients with assessments at baseline and
12 months. Baseline data were used to assess the internal reliability and validity of the measures. Both anchor-
based and distribution-based approaches were employed for estimating RD. Anchor-based estimates were based
on published RD values for the EQ-5D and were assessed for those improving and deteriorating separately.
Distribution-based estimates were based on standard error of measurement (SEM), change score equivalent to 0.30,
and change score equivalent to 0.50, effect sizes (ES).
Results: The sample included 911 RRMS patients (67.3% female, age mean (SD) 36.2 (8.4) years, duration of MS mean
(SD) 4.8 (5.2) years). Results showed that the PRIMUS and U-FIS had good internal consistency. Appropriate correlations
were observed with comparator instruments and both measures were able to distinguish between participants based
on Expanded Disability Status Scale scores and time since diagnosis. The anchor-based and distribution-based RD
estimates were: PRIMUS Activities range = 1.2-2.3, PRIMUS QoL range = 1.0-2.2, and U-FIS range = 2.4-7.0.
Conclusions: The results show that the PRIMUS and U-FIS are valid instruments for use with RRMS patients. The
analyses provide preliminary information on how to interpret scores on the scales. These data will be useful for
assessing treatment efficacy and for powering clinical studies.
Trial Reference Number: ClinicalTrials.gov Identifier NCT00340834.
Background
Multiple sclerosis (MS) is a chronic, autoimmune and
neurodegenerative disorder of the central nervous sys-
tem (CNS) characterized by inflammation, demyelina-
tion and neuronal loss. MS represents the leading
cause of non-traumatic neurologic disability in young
and middle-aged adults, affecting an estimated 2.5 mil-
lion individuals worldwide [1]. About 85% of patients
begin with the Relapse Remitting form of MS (RRMS)
which is characterised by episodes of symptoms fol-
lowed by resolution, at least partly, within days to
months [2,3]. The long term clinical effects of MS
often lead to serious disability. Symptoms of MS are
wide ranging and can include weakness of the limbs
(particularly the legs), fatigue, unsteadiness, difficulty
with bladder control, visual changes due to the invol-
vement of the optic nerve, vertigo, facial numbness or
weakness or double vision [4]. In addition, depression
occurs in about a quarter of patients [5]. Unsurpris-
ingly, the disease can have major detrimental effects
on a patient’s QoL [3,6,7].
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for developing understanding and treatment of this dis-
ease. The Patient Reported Indices for Multiple Sclerosis
(PRIMUS) was developed to capture the overall impact
of MS from the patient’sp e r s p e c t i v e[ 8 ] .T h i si n s t r u -
ment consists of three distinct scales specific to MS;
symptoms, activity limitations and quality of life (QoL),
each designed to be used in combination or as a standa-
lone measure. Scale content was generated directly from
MS patients and, consequently closely represents
patients’ experience of MS. As fatigue is present in
about three quarters of patients [9] the Unidimensional
Fatigue Impact scale (U-FIS) [10] was developed in par-
allel with the PRIMUS scales to provide an index of the
impact of fatigue associated with MS. The PRIMUS and
U-FIS scales were developed and validated in patients
representing the most common MS sub-types; RRMS,
Secondary Progressive MS and Primary Progressive MS
[8,10]. Data from a large 12 month efficacy trial were
made available to evaluate the validity of the instru-
ments further specifically for RRMS. These data also
provided an opportunity to investigate how to interpret
scores for the PRIMUS and U-FIS.
One of the most commonly used approaches for inves-
tigating how to interpret scores on Patient Reported Out-
come (PRO) scales has been through the calculation of a
minimum score that can be considered to be clinically
meaningful. This score can then be used to help interpret
treatment response during therapeutic trials. Calculation
of this score has been referred to as the Minimal Impor-
tant Difference (MID) [11], meaningful change [12] and
minimal clinically significant difference [13]. More
recently the term Responder Definition (RD) has replaced
previous terminology [14].
No single method for estimating the RD is widely
accepted. Approaches can be classified broadly into
anchor-based and distribution-based approaches.
Anchor-based approaches involve relating change scores
on the PRO to change in a factor of known importance.
These methods usually involve using other PROs,
[11,15,16] clinical variables [17,18] or patient global rat-
ing of change questions [12,19,20] as an anchor. Each
approach has strengths and limitations. Other compara-
tor instruments can only be used when the instruments
are suitably related to the testing instrument and cover
issues important and relevant to the patient [21]. Some
authors have suggested that a correlation of 0.5 is neces-
sary between the anchor and main instrument in order
to ensure adequate relatedness [15,16]. In these cases it
is also useful if previous research has investigated the
RD of the comparator instrument. Clinical variables can
provide useful markers for interpreting scores on PROs
but they do not provide minimal important difference
estimates per se. These are most useful when other
information for estimating RD is unavailable. Global
Rating of Change (GRC) questions generally have multi-
ple Likert type response options ranging from ‘very
much worse’ to ‘very much better’.C h a n g es c o r e sf o r
those individuals responding ‘a little’ or ‘moderately’
improved are used to estimate the RD. Although global
rating of change questions are easy to administer the
reliability of such methods is questionable. Doubt exists
about whether patients can recall their health over peri-
ods of time and it is unknown whether patients respond
primarily in relation to their current health rather than
their change in health [22]. It has also been argued that
estimation of RD should not be based on GRC items
alone [21].
Distribution-based approaches assess the distribution
of scores on the PRO and attempt to identify a score that
may be considered important above the ‘statistical noise’
of the measure. Various distribution-based approaches
have been suggested including effect size [23], half a stan-
dard deviation [24], the standard error of measurement
(SEM) [25] and the standard response mean (SRM) [26].
These different approaches usually produce different
magnitudes of RD. Furthermore, distribution-based esti-
mates can sometimes differ considerably from those
obtained using anchor-based methods [27].
No previous study has attempted to determine the RD
of the PRIMUS and U-FIS. The aim of the present study
was twofold. First, to provide further evidence of the
validity of the PRIMUS and U-FIS in a RRMS sample.
Secondly, to investigate the RD of the PRIMUS and
U-FIS scales.
Methods
Patients
Analyses were based on data collected in a 12-month,
randomized, multicenter, double-blind, efficacy trial
where patients were randomized to receive a fixed dose
o fe i t h e rF T Y 7 2 00 . 5m g / d a yo r a l l y ,F T Y 7 2 01 . 2 5m g /
d a yo r a l l yo ri n t e r f e r o nb e t a - 1 a3 0μg/week. The trial
included 1292 RRMS patients at 172 centers in 18 coun-
tries. PRIMUS and U-FIS data were only available for
countries where the questionnaires had been previously
formally adapted and validated [8,28,10,29]. Data were
available for 911 patients from the following 8 countries;
Canada (French and English), France, Germany, Italy,
Spain, United Kingdom, United States and Australia.
The participants were aged 18 to 55 years, with active
MS (defined as one relapse during the previous year or
two relapses during the previous 2 years), Expanded
Disability Status Scale (EDSS) score of between 0 and
5.5 and neurologically stable for at least 30 days prior to
randomization.
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The PRIMUS consists of three independent scales;
symptoms, activity limitations and QoL designed to be
used as standalone measures or in combination [8,28].
For the present study data were available for the QoL
and activity limitation scales. The QoL scale contains
22-items in the form of simple statements accompanied
by dichotomous response options. Items are summed in
each scale to yield a total score ranging from 0 to 22.
High scores indicate worse QoL. The activity limitations
scale contains 15-items describing specific physical
tasks. Respondents rate the degree to which they are
able to perform the tasks on a three point scale. Again,
items are summed to give a total score that can range
from 0 to 30. High scores are indicative of greater activ-
ity limitation. Both scales have been shown to be unidi-
mensional and to have good reproducibility and validity
in a number of languages [28].
The U-FIS has 22-items measuring the impact of fati-
gue [10,29]. For each item, individuals rate the degree to
which they have been affected by fatigue during the pre-
vious week on a scale ranging from ‘Never’ (scored 0) to
‘All the time’ (scored 3). Item scores are summed to
g i v eat o t a ls c o r et h a tc a nr a n g ef r o m0t o6 6 .T h e
U-FIS is unidimensional and has been shown to have
good reproducibility and validity in several languages
[29]. The PRIMUS and U-FIS are available at http://
www.galen-research.com.
The Expanded Disability Status Scale (EDSS) is a global
scale developed to evaluate disability due to neurologic
limitations in people with MS [30]. It has 20 available
levels that describe progressive disability ranging from 0
(normal) to 10 (death due to MS) rising in 0.5 units.
Patients are clinically assessed and assigned scores in
eight functional systems that are scored from 0-5 or 0-6.
Higher scores represent greater system impact. The eight
functional systems are; pyramidal, cerebellar, brainstem,
sensory, bowel and bladder, visual and cerebral/mental
functions. EDSS scores are generated from the system
functions scores and other information collected during
the clinical examination.
The Multiple Sclerosis Functional composite (MSFC) is
a clinical measure of physical and cognitive functioning in
MS patients [31]. It assesses leg function/ambulation, arm/
hand function and cognitive function. These three scales
are also added together to give a composite measure of
functioning. The leg function/ambulation measure is
based on the average of two timed 25-foot walk tests. The
arm/hand function measure involves four 9-hole peg tests.
The cognitive function measure is the Paced Auditory
Serial Addition Test (PASAT) that assesses auditory pro-
cessing speed and working memory [32]. The three sepa-
rate scale scores are converted into z-scores before being
added together to form a composite score.
The EQ-5D is a generic health outcome assessment
[33]. It consists of 5 items: Mobility, Self-care, Usual
activities, Pain/Discomfort and Anxiety/depression, each
with 3 levels (no problems, moderate problems, extreme
problems). A health utility value is derived for each
patient based on their combination of responses to the
five items. The score is on a continuum from 1 (best
possible health) to 0 (death) with some health states
being valued worse than death (< 0). Research has sug-
gested that the RD of the EQ-5D is 0.074 [34].
Statistical analysis
Reliability and Validity
The distributional properties of the PRIMUS and U-FIS
were explored through descriptive statistics (mean, standard
deviation, median and inter-quartile range [IQR]) and floor
and ceiling effects (percentage of patients scoring the mini-
mum and maximum possible scores, respectively). Internal
consistency (degree of relatedness of items) was assessed
using Cronbach’s alpha. A correlation of 0.70 is accepted as
indicating adequate consistency [35]. Convergent and discri-
minant validity were evaluated by assessing the level of asso-
ciation (Spearman rank correlations) between scores on the
PRIMUS and U-FIS scales and those on the EQ-5D, EDSS
and the MSFC subscales and composite score. Known
groups validity was assessed by examining the PRIMUS and
U-FIS scores of respondents who differed according to their
baseline EDSS group and duration of MS. EDSS group was
defined in the following way; EDSS (0 - 1.5), EDSS (2 - 2.5),
EDSS (3 - 3.5), EDSS (4-5.5). Non-parametric tests for inde-
pendent samples (Mann-Whitney U Test for two groups
and Kruskal-Wallis one-way analysis of variance for three or
more groups) were employed. Psychometric testing was
performed using the SPSS 17.0 statistical package.
Responder Definition Analysis
The RDs for the PRIMUS and U-FIS were estimated using
a combination of anchor-based and distribution-based
methods. Anchor-based analyses were conducted by com-
paring scores on the PRIMUS and U-FIS with published
RD values for the EQ-5D [34]. The anchor approach
assessed change scores for the PRIMUS and U-FIS for
individuals who improved or deteriorated by 0.074-0.111
on the EQ-5D (1-1.5 times the RD of the EQ-5D).
The distributional methods included the assessment of
effect size, half a standard deviation and standard error
of measurement. The effect size (ES) statistic is based
on the ratio of difference between a target measure’s
mean at baseline and at follow-up (related to the stan-
dard deviation of the baseline scores). The group change
ES is calculated as follows:
ES
mm
s
=
− () 21
1
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group mean at follow-up and s1 is the group standard
deviation at baseline. Cohen devised ES thresholds for
assessing the magnitude of group change that are widely
accepted [23]. These are 0.2 for a small group change,
0.5 for a moderate group change and 0.8 for a large
group change. Estimates of change scores needed to
produce different effect sizes can be calculated using
baseline standard deviations. Half a standard deviation
(equivalent to half the baseline standard deviation) is
commonly found to be close in value to published RD
values [24]. Change scores required to produce effect
sizes of 0.3, and 0.5 were calculated.
The SEM has also been posited as a surrogate for the
RD [25]. It has been described as the standard error in
an observed score that obscures the true score [36]. It is
estimated as follows:
SEM s r =× − () 1 1
Standard deviation at baseline (s1) is multiplied by the
square root of one minus the internal consistency of the
target measure (as assessed by Cronbach’s Alpha coeffi-
cient (r)). SEM has been used frequently to aid in the
interpretation of PRO scores and a change above 1 SEM
has been considered to be meaningful [37-40].
Results
Demographic and disease information for the sample is
shown in Table 1. The table shows that the sample was
relatively mild in terms of MS severity. A majority of
patients had EDSS scores between 0 and 2.5 and most
reported having had two or fewer relapses in the pre-
vious two years.
Questionnaire responses on the PRIMUS, U-FIS and
EQ-5D are reported in Table 2. Results showed that
over 20% of respondents scored the minimum for the
PRIMUS Activity limitations and QoL scale and the
maximum for the EQ-5D scale (which indicates good
health status). These findings confirm the relatively low
baseline disability in the sample. Results showed that
there were few signs of ceiling effects for the PRIMUS
or U-FIS scales.
Internal consistency
Cronbach’s alpha coefficients for the scales were; PRI-
MUS Activities 0.88, PRIMUS QoL 0.92, and U-FIS
0.97. As cronbach’s alpha coefficients were all above 0.7
this indicated good interrelatedness of items.
Convergent validity
Correlations between questionnaire and physician
assessments are shown in Table 3. As anticipated, mod-
erate correlations were found between the PRIMUS
Table 1 Participant details (n = 911)
Sex
Male (%) 292 (32.1)
Female (%) 618 (67.8)
Missing (%) 1 (0.1)
Age (years)
Mean (SD) 36.5 (8.4)
Median (IQR) 37 (30 - 43)
Range 18 - 55
Missing (%) 0
Duration of MS (years)
Mean (SD) 4.8 (5.2)
Median (IQR) 3.2 (0.7 - 7.2)
Range 0.1 - 32.9
Missing (%) 9 (1)
Number (%) relapses in the previous 2 years
1 268 (29.4)
2 536 (58.8)
3 86 (9.4)
4 18 (2.0)
Missing (%) 3 (0.3)
EDSS Group (%)
0-1.5 400 (44.3)
2-2.5 262 (29.0)
3-3.5 135 (15.0)
4+ 105 (11.6)
Missing (%) 9 (1)
Table 2 Descriptive scores on patient reported outcome
measures
PRIMUS
QoL
PRIMUS
Activities
UFIS EQ-5 D
Utility
Baseline
N 885 883 873 900
Mean (SD) 4.0 (4.3) 3.0 (4.6) 16.8 (13.9) 0.80 (0.19)
Median
(IQR)
2.0 (1.0 -
6.0)
2.0 (0 - 4.0) 14.0 (5.0 -
27.0)
0.80 (0.73 -
1)
% scoring
Min
21.4 39.8 7.0 0
% scoring
Max
0 0.2 0 29.9
12 Months
n 835 833 825 839
Mean (SD) 3.8 (4.7) 3.2 (4.8) 17.0 (14.8) 0.80 (0.21)
Median
(IQR)
2.0 (0 - 6.0) 1.0 (0 - 4.0) 13.0 (4.0 -
27.0)
0.81 (0.73 -
1)
% scoring
Min
29.8 41.5 10.4 0
% scoring
Max
0.2 0.4 0.2 35.2
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but distinct constructs. The PRIMUS scales and the U-
FIS correlated strongly wi t he a c ho t h e r .T h eE D S S
showed low to moderate correlations with the PRIMUS
scales and with the U-FIS. The PRIMUS QoL scale and
the U-FIS showed weak associations with the MSFC
scales and composite score. The PRIMUS Activities
scale showed slightly stronger associations with the
MSFC scales and composite but these still remained
lower than expected. It should be noted that the EDSS
and the EQ-5D also showed lower than expected corre-
lations with the MSFC composite score and its sub-
scales. In particular, all scales correlated weakly with the
MSFC PASAT scores.
Known group validity
Results of the known group validity assessments for the
PRIMUS and U-FIS sales are shown in Table 4. Each of
the scales was able to distinguish between participants
based on EDSS group. As expected, individuals with
greater disability according to EDSS had significantly
higher PRIMUS and U-FIS scores. The PRIMUS scales
and U-FIS were also able to distinguish between partici-
pants based on their duration of MS. As anticipated,
individuals who had experienced MS for longer had sig-
nificantly higher scores on the scales. The PRIMUS
scales and U-FIS were also able to distinguish between
individuals based on the number of relapses they had
experienced in the previous two years. Significant differ-
ences in PRIMUS activity limitations and U-FIS scores
were found between groups split by number of relapses
in the previous two years. Individuals with more relapses
obtained higher scores. There was a similar, but not sta-
tistically significant, finding for QoL scores. However,
both the PRIMUS QoL and U-FIS scales showed statisti-
cally significant differences between patients who
reported two relapses compared with those who
reported three or more.
Table 3 Convergent validity PRIMUS QoL, PRIMUS Activities and U-FIS at baseline
PRIMUS
QoL
PRIMUS
Activities
U-FIS Timed
25 foot
Walk test
9-hole
peg
test
PASAT MSFC
Total
EDSS
PRIMUS Activities .62
U-FIS .75 .66
Timed 25 foot Walk test .20 .32 .22
9-hole peg test .20 .31 .22 .31
PASAT -.17 -.18 -.18 -.20 -.20
MSFC Total -.24 -.33 -.25 -.47 -.72 .71
EDSS .35 .65 .38 .27 .34 -.14 -.31
EQ-5 D Utility -.58 -.58 -.60 -.20 -.23 .14 .24 -.35
All correlations were significant at the <0.01 level (2 tailed, Spearman Rank correlations)
Table 4 Known Group Validity at baseline
PRIMUS QoL PRIMUS Activities UFIS
n Mean (SD) n Mean (SD) n Mean (SD)
EDSS Group
0-1.5 391 2.7 (3.5) 393 1.6 (3.5) 381 11.7 (11.0)
2-2.5 255 3.8 (4.0) 253 2.7 (3.8) 252 17.6 (13.7)
3-3.5 130 5.3 (4.6) 129 4.5 (5.4) 129 22.2 (14.4)
4-5.5 102 7.4 (5.2) 99 7.7 (5.5) 102 27.1 (14.8)
P < 0.01 < 0.01 < 0.01
Number of relapses in previous 2 years
1 259 3.8 (4.3) 260 2.2 (3.4) 262 16.1 (13.8)
2 522 3.8 (4.1) 519 3.1 (4.7) 508 16.2 (13.4)
3+ 101 5.1 (5.3) 101 4.7 (6.3) 100 22.1 (15.4)
P 0.084 < 0.01 < 0.01
Median MS duration group
Below median (3.2) 439 3.6 (4.2) 435 2.3 (4.1) 435 14.5 (13.3)
Above median (3.2) 439 4.3 (4.4) 439 3.8 (5.0) 429 19.1 (14.1)
P < 0.01 < 0.01 < 0.01
Non-parametric tests were conducted (Mann-Whitney U Test for two groups and Kruskal-Wallis one-way analysis of variance for three or more groups)
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The anchor-based estimates for the RD for those
improving and deteriorating are shown in Table 5. The
results showed that for the PRIMUS Activities and QoL
scales the RD estimates were similar for patients who
improved or deteriorated. There was a more pro-
nounced difference in RD estimates between patients
who improved or deteriorated according to the U-FIS.
Note that scores for no change in EQ-5D provided the
following change scores; -0.2 (n = 331) for Activity lim-
itations, 0.3 (n = 331) for QoL and 0.0 (n = 325) for U-
FIS.
Values for the distribution-based approaches (SEM
and ES) are also shown in Table 5. The distribution-
based estimates provided similar values to the anchor-
based estimates.
The final ranges in RD values for each scale were PRI-
MUS QoL 1.0-2.2, Activities 1.2-2.3 and U-FIS 2.4-7.0.
Discussion
The results of this study support the use of the PRIMUS
and U-FIS with Relapse Remitting MS samples. Ques-
tionnaire descriptive statistics confirmed the mild sever-
ity of the sample demonstrated by the clinical data.
Internal consistency was above 0.70 for the PRIMUS
and U-FIS scales indicating that items in the scales were
sufficiently related. Convergent and divergent validity
showed that the PRIMUS and U-FIS scales had the
expected patterns of association with the comparator
measures. Scores on the PRIMUS and U-FIS scales were
also related to each other in the same way as was found
in previous research involving a wider range of types of
MS [8,10]. Associations between the PRIMUS and U-
FIS and the MSFC subscales and composite score were
weaker than expected. However, associations between
the MSFC, EDSS and EQ-5D were also weaker than
expected suggesting that further investigation of the
relation between the MSFC and other clinical outcome
measures is needed [41-44].
Known groups validity results showed that the PRI-
MUS scales and the U-FIS were able to distinguish
between participants based on their EDSS level and
duration of illness. The PRIMUS and U-FIS scales were
also able to distinguish between participants based on
the number of relapses they had experienced in the pre-
vious two years, although, this difference was not statis-
tically significant for the PRIMUS QoL scale. However,
it may be more appropriate to measure relapse fre-
quency yearly or 6 monthly to provide more accurate
information.
The anchor estimates produced preliminary evidence
of the RDs for the PRIMUS and U-FIS. Encouragingly,
the scores obtained for the anchor-based estimates were
similar in value to those obtained from the distribution-
based estimates. Previous research has suggested that
there may be differences in RD values depending on
whether individuals improve or deteriorate [45-47]. In
the present study there was no bi-directional difference
in anchor-based RD values for individuals who improved
or deteriorated for the PRIMUS Activities and QoL
scales. However, there was a bi-directional difference for
the U-FIS; individuals who improved had an RD of 6.5
compared with 4.7 for those who deteriorated. Despite
this difference both the improving and deteriorating
anchor values for the U-FIS were within the range of
the distribution-based estimates. It is unclear whether
there are true differences in the RD values for indivi-
duals with improving or deteriorating scores on the U-
FIS. Further research is needed to investigate this issue.
The final range in values for each scale can be used to
provide preliminary guidance when interpreting changes
in scores on the measures and to aid calculation of sam-
ple sizes needed for clinical studies. Future research is
needed to determine whether the RD estimates remain
constant in more severe samples and with different
types of MS. Previous researchers have highlighted the
possibility that the RD may vary as a function of severity
[13,21]. For example, it is possible that individuals with
Table 5 Responder definition estimates
PRIMUS Activities PRIMUS QoL U-FIS
Responder Definition Estimates n Mean
change
score
n Mean
change
score
n Mean
change
score
Anchor-based
Equivalent to reported EQ-5 D RD improvement 16 -2.3 17 -1.0 17 -6.5
Equivalent to reported EQ-5 D RD deterioration 15 1.8 15 1.0 15 4.7
Distribution-based
SEM 814 1.2 812 1.5 815 2.4
Change score equivalent to 0.30 ES 814 1.4 812 1.3 815 4.2
Change score equivalent to 0.50 ES 814 2.3 812 2.2 815 7.0
Distribution-based estimates were conducted at baseline
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higher RDs for the scales. The present study investigated
the RDs of the PRIMUS and U-FIS in a fairly mild sam-
p l eo fR Mp a t i e n t sa n dt h er e s u l t sc a nb ec o n s i d e r e d
valid for future similar samples.
The study has a number of limitations. As mentioned
earlier, the sample included a high proportion of
patients at the low end of the MS disability spectrum.
However, this is consistent with recent clinical trials of
RRMS patients and is likely to be reflected in future
RRMS studies where the PRIMUS and UFIS are applied.
The present assessments were unable to report on the
reproducibility of the PRIMUS and U-FIS scales in this
sample. However, previous research, including a large
proportion of RRMS patients, indicated that the scales
had excellent reproducibility [8,10,28,29]. Anchor-based
estimates of RD were based on the published RD value
for the EQ-5D. Although this provided a useful tool for
the present study there are other potential anchors that
could be used such as a global question on change in
overall health. Finally, as there was little change in
patient condition during the trial, relatively few patients
could be included in the RD anchor analysis.
Conclusions
The PRIMUS and U-FIS have been shown to be reliable
and valid instruments for the assessment of outcome in
RRMS patients. RD estimates are between 1.2-2.3 for
the PRIMUS Activity scale, 1.0-2.2 for the QoL scale
and 2.4-7.0 for the U-FIS. These estimates are important
to help interpretation of change scores and to assist in
determining sample sizes necessary for future clinical
studies.
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